Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology
dc.contributor.author
dc.date.accessioned
2016-05-23T09:54:40Z
dc.date.available
2016-05-23T09:54:40Z
dc.date.issued
2016-01-25
dc.identifier.uri
dc.description.abstract
Background
There is still no reliable biomarker for the diagnosis of pancreatic adenocarcinoma. Carbohydrate
antigen 19–9 (CA 19–9) is a tumor marker only recommended for pancreatic adenocarcinoma
follow-up. One of the clinical problems lies in distinguishing between this
cancer and other benign pancreatic diseases such as chronic pancreatitis. In this study we
will assess the value of panels of serum molecules related to pancreatic cancer physiopathology
to determine whether alone or in combination could help to discriminate between
these two pathologies.
Methods
CA 19–9, carcinoembryonic antigen (CEA), C-reactive protein, albumin, insulin growth factor-
1 (IGF-1) and IGF binding protein-3 were measured using routine clinical analyzers in a
cohort of 47 pancreatic adenocarcinoma, 20 chronic pancreatitis and 15 healthy controls.
Results
The combination of CA 19–9, IGF-1 and albumin resulted in a combined area under the
curve (AUC) of 0.959 with 93.6% sensitivity and 95% specificity, much higher than CA 19–9
alone. An algorithm was defined to classify the patients as chronic pancreatitis or pancreatic
cancer with the above specificity and sensitivity. In an independent validation group of 20 pancreatic adenocarcinoma and 13 chronic pancreatitis patients, the combination of the four molecules classified correctly all pancreatic adenocarcinoma and 12 out of 13 chronic pancreatitis patients.
Conclusions
Although this panel of markers should be validated in larger cohorts, the high sensitivity and
specificity values and the convenience to measure these parameters in clinical laboratories
shows great promise for improving pancreatic adenocarcinoma diagnosis
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
Public Library of Science (PLoS)
dc.relation.isformatof
Reproducció digital del document publicat a: http://dx.doi.org/10.1371/journal.pone.0147214
dc.relation.ispartof
PLoS One, 2016, vol. 11, núm. 1, p.e0147214
dc.relation.ispartofseries
Articles publicats (D-B)
dc.rights
Attribution 3.0 Spain
dc.rights.uri
dc.subject
dc.title
Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology
dc.type
info:eu-repo/semantics/article
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.embargo.terms
Cap
dc.type.version
info:eu-repo/semantics/publishedVersion
dc.identifier.doi
dc.identifier.idgrec
024290
dc.identifier.eissn
1932-6203